Clik here to view.
In conversation with Kelly Close
Kelly Close As president and founder of Close Concerns, a healthcare information firm focused on diabetes and obesity, Kelly Close says her passion comes from her extensive professional work as well as...
View ArticleClik here to view.
Transition moves into late-stage drug development
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate,...
View ArticleClik here to view.
In conversation with Steve Damon
Steve Damon As president, CEO and a co-founder of closely-held 4P Therapeutics, a leading developer of transdermal patches, Steve Damon cut his teeth in the sector at Altea Therapeutics and Durect. He...
View ArticleClik here to view.
Stifel starts vTv Therapeutics at buy
Stifel has initiated coverage of vTv Therapeutics (NASDAQ:VTVT) with a “buy” rating and $17 price target, pointing to its significant Alzheimer’s disease (AD) and diabetes assets. The stock closed at...
View ArticleClik here to view.
Oramed sees value creating events through 2016
Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. Josh Hexter They include completion of an ongoing Phase 2b FDA...
View ArticleClik here to view.
Transition Therapeutics reports TT401 trial results
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered...
View ArticleClik here to view.
Oramed gets Indian patent for oral administration of proteins
Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to...
View Article
